43 results about "Thymic stromal lymphopoietin" patented technology

The present disclosure provides compositions and methods relating to antigen binding proteins which bind to human thymic stromal lymphopoietin (TSLP), including antibodies. In particular embodiments, the disclosure provides fully human, humanized and chimeric anti-TSLP antibodies and derivatives of such antibodies. The disclosure further provides nucleic acids encoding such antibodies and antibody fragments and derivatives, and methods of making and using such antibodies including methods of treating and preventing TSLP-related inflammatory and fibrotic disorders.

The invention provides methods and compositions for reducing or preventing fibrosis in a subject suffering from a fibrotic disorder by administering a therapeutically effective amount of at least one antagonist to the cytokine thymic stromal lymphopoietin to the subject. In one embodiment, the methods and compositions further comprise administering at least one additional antagonist to an additional profibrotic cytokine, growth factor or chemokine.

Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.

The present invention discloses a canine TSLP protein and a nucleic acid that encodes that protein. Peptide fragments of the protein that comprise specific epitopes of the canine TSLP protein are also disclosed. The canine TSLP protein and related peptide fragments may be used as an antigen for immunological assays, as well as for vaccines that induce anti-TSLP antibodies. The present invention further discloses methods of making and using the canine TSLP gene, the canine TSLP protein, and the related peptide fragments.

The invention provides an anti-human thymic stromal lymphopoietin (TSLP) monoclonal antibody and an application thereof. The anti-human thymic stromal lymphopoietin (TSLP) monoclonal antibody comprises three heavy chain complementary determining regions (CDR-H1, CDR-H2 and CDR-H3) and three light chain complementary determining regions (CDR-L1, CDR-L2 and CDR-L3), and (a) the amino acid sequence of the CDR-H1 is as shown in SEQ ID NO: 1, and (b) the amino acid sequence of CDR-H2 is as shown in SEQ ID NO: 2; (c) the amino acid sequence of the CDR-H3 is as shown in SEQ ID NO: 3; (d) the amino acid sequence of the CDR-L1 is as shown in SEQ ID NO: 4; (e) the amino acid sequence of the CDR-L2 is as shown in SEQ ID NO: 5; and the amino acid sequence of the (f) CDR-L3 is as shown in SEQ ID NO: 6. Compared with an anti-human TSLP monoclonal antibody Tezepelumab (prepared according to sequence expression disclosed in the patent), the anti-human TSLP monoclonal antibody has the advantages that the affinity of the anti-human TSLP monoclonal antibody combined with the human TSLP is equivalent, the neutralizing activity of the anti-human TSLP monoclonal antibody at the cellular level is superior to that of the Tezepelumab, and the anti-human TSLP monoclonal antibody is expected to show a good clinical effect in the aspect of preventing and treating related diseases.

The invention provides methods and compositions for reducing or preventing fibrosis in a subject suffering from a fibrotic disorder by administering a therapeutically effective amount of at least one antagonist to the cytokine thymic stromal lymphopoietin to the subject. In one embodiment, the methods and compositions further comprise administering at least one additional antagonist to an additional profibrotic cytokine, growth factor or chemokine.

The present disclosure encompasses compositions and methods for the treatment of precancerous skin lesions. Compositions of the invention comprise a cytotoxic agent and a thymic stromal lymphopoietin (TSLP) inducer.

The present invention relates to a compound for inhibiting thymic stromal lymphopoietin (TSLP) secretion from mast cells and use thereof. The compound of the present invention was confirmed to significantly inhibit TSLP secretion from mast cells and, accordingly, may be used as a candidate compound for treating and preventing atopic dermatitis, allergic dermatitis, and / or inflammatory bowel disease.

The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of thymic stromal lymphopoietin (TSLP). The invention also includes pharmaceutical compositions comprising said peptide ligands and to the use of said peptide ligands in preventing, suppressing or treating a disease or disorder mediated by TSLP.

The present invention relates to human thymic stromal lymphopoietin (hTSLP) antibodies and especially those which neutralize hTSLP activity. It further relates to methods for using anti-hTSLP antibody molecules in diagnosis or treatment of hTSLP related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis inflammatory bowel disease, and Hodgkin's lymphoma.

This application provides an anti-human thymus stromal lymphopoietin (TSLP) monoclonal antibody and its application. The anti-human thymus stromal lymphopoietin (TSLP) monoclonal antibody of the present application comprises three heavy chain complementarity determining regions (CDR‑H1, CDR‑H2 and CDR‑H3) and three light chain complementarity determining regions (CDR‑L1 , CDR‑L2 and CDR‑L3), wherein, (a) the amino acid sequence of CDR‑H1 is shown in SEQ ID NO: 1; (b) the amino acid sequence of CDR‑H2 is shown in SEQ ID NO: 2; (c ) The amino acid sequence of CDR‑H3 is shown in SEQ ID NO: 3; (d) the amino acid sequence of CDR‑L1 is shown in SEQ ID NO: 4; (e) the amino acid sequence of CDR‑L2 is shown in SEQ ID NO: 5 and (f) the amino acid sequence of CDR-L3 is shown in SEQ ID NO:6. The anti-human thymus stromal lymphopoietin (TSLP) monoclonal antibody, compared with the anti-human TSLP monoclonal antibody Tezepelumab (expressed and prepared according to the sequence disclosed in the patent), has comparable affinity for binding human TSLP, and is in the cell level. It is more active than Tezepelumab and is expected to show good clinical effects in the prevention and treatment of related diseases.

The present invention relates to a pharmaceutical composition for preventing or treating allergic diseases such as asthma or atopy including baicalein as an active ingredient. Baicalein is capable of regulating thymic stromal lymphopoietin-mediated signal transduction. The pharmaceutical composition of the present invention can effectively suppress inflammatory responses of allergic or asthmatic diseases due to the presence of baicalein extracted from Scutellariae Radix that regulates TSLP-mediated intracellular signal transduction to inhibit intracellular phosphorylation of STATS and inhibit the binding of TSLP to TSLPR. In addition, the pharmaceutical composition of the present invention may further include one or more compounds having synergistic effects with baicalein. In this case, the pharmaceutical composition can more effectively suppress inflammatory responses of allergic diseases such as asthma or atopy.

The present disclosure relates to antibodies (e.g., human antibodies) and antigen-binding fragments thereof that specifically bind to and neutralize (human) thymic stromal lymphopoietin (TSLP). Such molecules can have modified Fc regions that have the ability to increase antibody half-life, increase resistance to proteases, and / or reduce interaction with Fc gamma receptors. These molecules are useful for the treatment of allergic and non-allergic inflammation associated with TSLP related disorders or diseases.

The invention relates to the technical field of antibodies, in particular to a human thymus stromal lymphopoietin monoclonal antibody and an application thereof. The TSLP antibody provided by the present invention can specifically bind hTSLP with high affinity, and can effectively inhibit the binding of TSLP to its receptor, thereby inhibiting TSLP from activating downstream signaling pathways and activating immune cells. The TSLP antibody provided by the present invention is used for the content detection of hTSLP and allergic asthma, chronic obstructive pulmonary disease, allergic dermatitis, allergic rhinitis, allergic sinusitis, eosinophilic esophagitis, allergic conjunctivitis, inflammatory bowel disease It is of great significance in the diagnosis, treatment and prognosis of inflammatory or allergic inflammatory diseases such as atopic dermatitis or atopic dermatitis.